In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Chiron acquires PathoGenesis for $729mm

Executive Summary

Strengthening its infectious disease vaccines and therapeutics business, Chiron will acquire antibiotic developer PathoGenesis for $729mm in cash, paying $38.50 per share for each of the company's 19mm outstanding shares, a (pr)22% premium to its market average, or about 12 times its 1999 sales.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Full Acquisition

Related Companies